Residents

AB Initio Biotherapeutics

AB Initio Biotherapeutics

At Ab Initio, we are using a proprietary directed evolution engineering technology to create next-generation biologics, including antibodies that modulate the signaling activity of G-protein coupled receptors (GPCRs).

Area of focus: 
Oncology
Commencement date: 
04/01/2015

Share